Skip to Main Content

Author Details

Carmel Murone
Olivia Newton-John Cancer Research Institute
1994
50
24
PMIDPaper TitleJournal TitlePublished Year
36765160Author Correction: DUSP5 is methylated in CIMP-high colorectal cancer but is not a major regulator of intestinal cell proliferation and tumorigenesis.Sci Rep2023
35565421Paracrine IL-6 Signaling Confers Proliferation between Heterogeneous Inflammatory Breast Cancer Sub-Clones.Cancers (Basel)2022
35404015A phase 1 safety and bioimaging trial of antibody DS-8895a against EphA2 in patients with advanced or metastatic EphA2 positive cancers.Invest New Drugs2022
33453471Expression of EGFR and conformational forms of EGFR in malignant pleural mesothelioma and its impact on survival.Lung Cancer2021
33035778Analysis of angiogenic and stromal biomarkers in a large malignant mesothelioma cohort.Lung Cancer2020
31106127Mesenchyme to epithelial transition protein expression, gene copy number and clinical outcome in a large non-small cell lung cancer surgical cohort.Transl Lung Cancer Res2019
27452367Metabolic response evaluation for colorectal liver metastases and correlation to pathologic response and tumour markers.ANZ J Surg2018
30052660Development of monoclonal anti-PDGF-CC antibodies as tools for investigating human tissue expression and for blocking PDGF-CC induced PDGFRα signalling in vivo.PLoS One2018
29527009Phase II study of everolimus (RAD001) monotherapy as first-line treatment in advanced biliary tract cancer with biomarker exploration: the RADiChol Study.Br J Cancer2018
29379130DUSP5 is methylated in CIMP-high colorectal cancer but is not a major regulator of intestinal cell proliferation and tumorigenesis.Sci Rep2018
28257959The Immune Microenvironment, Genome-wide Copy Number Aberrations, and Survival in Mesothelioma.J Thorac Oncol2017
27104612PD-L1 and Tumor Infiltrating Lymphocytes as Prognostic Markers in Resected NSCLC.PLoS One2016
27753035Digital PCR of Genomic Rearrangements for Monitoring Circulating Tumour DNA.Adv Exp Med Biol2016
27780599Calretinin but not caveolin-1 correlates with tumour histology and survival in malignant mesothelioma.Pathology2016
27654651Correction: Molecular profiling of cetuximab and bevacizumab treatment of colorectal tumours reveals perturbations in metabolic and hypoxic response pathways.Oncotarget2016
26125443Vascular endothelial growth factor D expression is a potential biomarker of bevacizumab benefit in colorectal cancer.Br J Cancer2015
26517691Molecular profiling of cetuximab and bevacizumab treatment of colorectal tumours reveals perturbations in metabolic and hypoxic response pathways.Oncotarget2015
24569633A critical re-assessment of DNA repair gene promoter methylation in non-small cell lung carcinoma.Sci Rep2014
27408853In vivo imaging of cellular proliferation in renal cell carcinoma using 18F-fluorothymidine PET.Asia Ocean J Nucl Med Biol2014
25420155Hypoxia-controlled EphA3 marks a human endometrium-derived multipotent mesenchymal stromal cell that supports vascular growth.PLoS One2014
24995151Quantitative intratumoural microdistribution and kinetics of (131)I-huA33 antibody in patients with colorectal carcinoma.EJNMMI Res2014
25125683Targeting EphA3 inhibits cancer growth by disrupting the tumor stromal microenvironment.Cancer Res2014
23930204Prognostic impact and the relevance of PTEN copy number alterations in patients with advanced colorectal cancer (CRC) receiving bevacizumab.Cancer Med2013
23957735Global protein profiling reveals anti-EGFR monoclonal antibody 806-modulated proteins in A431 tumor xenografts.Growth Factors2013
22349300Villin expression is frequently lost in poorly differentiated colon cancer.Am J Pathol2012
23064761Sox9 drives columnar differentiation of esophageal squamous epithelium: a possible role in the pathogenesis of Barrett's esophagus.Am J Physiol Gastrointest Liver Physiol2012
21646616Impact of KRAS and BRAF Gene Mutation Status on Outcomes From the Phase III AGITG MAX Trial of Capecitabine Alone or in Combination With Bevacizumab and Mitomycin in Advanced Colorectal Cancer.J Clin Oncol2011
19882219Gene expression profiling of primary and metastatic colon cancers identifies a reduced proliferative rate in metastatic tumors.Clin Exp Metastasis2010
20980808Rarity of AKT1 and AKT3 E17K mutations in squamous cell carcinoma of lung.Cell Cycle2010
19825951Phase I biodistribution and pharmacokinetic study of Lewis Y-targeting immunoconjugate CMD-193 in patients with advanced epithelial cancers.Clin Cancer Res2009
17360479A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptors.Proc Natl Acad Sci U S A2007
17545534A phase I biodistribution and pharmacokinetic trial of humanized monoclonal antibody Hu3s193 in patients with advanced epithelial cancers that express the Lewis-Y antigen.Clin Cancer Res2007
16513609Correlation of hypoxic cell fraction and angiogenesis with glucose metabolic rate in gliomas using 18F-fluoromisonidazole, 18F-FDG PET, and immunohistochemical studies.J Nucl Med2006
17138734Lack of correlation of hypoxic cell fraction and angiogenesis with glucose metabolic rate in non-small cell lung cancer assessed by 18F-Fluoromisonidazole and 18F-FDG PET.J Nucl Med2006
15723450Immunological effects of chimeric anti-GD3 monoclonal antibody KM871 in patients with metastatic melanoma.Cancer Immun2005
16144944Treatment of human tumor xenografts with monoclonal antibody 806 in combination with a prototypical epidermal growth factor receptor-specific antibody generates enhanced antitumor activity.Clin Cancer Res2005
16000578A phase I trial of humanized monoclonal antibody A33 in patients with colorectal carcinoma: biodistribution, pharmacokinetics, and quantitative tumor uptake.Clin Cancer Res2005
16104907Assessing regional hypoxia in human renal tumours using 18F-fluoromisonidazole positron emission tomography.BJU Int2005
14676326Antitumor efficacy of cytotoxic drugs and the monoclonal antibody 806 is enhanced by the EGF receptor inhibitor AG1478.Proc Natl Acad Sci U S A2003
11454674Monoclonal antibody 806 inhibits the growth of tumor xenografts expressing either the de2-7 or amplified epidermal growth factor receptor (EGFR) but not wild-type EGFR.Cancer Res2001
11579119Specific targeting, biodistribution, and lack of immunogenicity of chimeric anti-GD3 monoclonal antibody KM871 in patients with metastatic melanoma: results of a phase I trial.J Clin Oncol2001
10385435Localization of bradykinin B2 receptors in the endometrium and myometrium of rat uterus and the effects of estrogen and progesterone.Endocrinology1999
9350649Localization of bradykinin B2 binding sites in rat kidney following chronic ACE inhibitor treatment.Kidney Int1997
9130669Distribution of bradykinin B2 receptors in sheep brain and spinal cord visualized by in vitro autoradiography.J Comp Neurol1997
9125666Acute and chronic in vivo inhibition of angiotensin-converting enzyme by perindopril in the endothelium and adventitia of large arteries and organs of the rabbit.J Cardiovasc Pharmacol1997
9236432Perindopril chronically inhibits angiotensin-converting enzyme in both the endothelium and adventitia of the internal mammary artery in patients with ischemic heart disease.Circulation1997
8856126Localization of bradykinin B2 receptors in sheep uterus.Immunopharmacology1996
8813637Characterization and localization of bradykinin B2 receptors in the guinea-pig using a radioiodinated HOE140 analogue.Eur J Pharmacol1996
7796134Angiotensin II receptor subtypes in the human central nervous system.Brain Res1995
7849569The stability of angiotensin receptors and angiotensin converting enzyme in post mortem brain.Neurochem Int1994
  • 1 - 50 of 50

Recommended Authors

Irina Kalatskaya
EMD Serono Research & Development Institute, Inc. (an affiliate of Merck KGaA)
Career Start Year 2003
Number of shared co-authors 1
Ping Guo
Steadman Philippon Research Institute, Center for Regenerative Sports Medicine
Career Start Year 2001
Number of shared co-authors 2
Annette T Byrne
Royal College of Surgeons in Ireland (RCSI)
Career Start Year 1999
Number of shared co-authors 0
David J Liewehr
Center for Cancer Research
Career Start Year 1999
Number of shared co-authors 0
Patrizia Moser
Medical University of Innsbruck
Career Start Year 1999
Number of shared co-authors 0
Theresa M LaVallee
Parker Institute for Cancer Immunotherapy
Career Start Year 1996
Number of shared co-authors 0
Jacqueline F Donoghue
University of Melbourne
Career Start Year 1995
Number of shared co-authors 2
Michael Bzorek
Zealand University Hospital
Career Start Year 1994
Number of shared co-authors 0
Mai Nguyen
University of California Riverside
Career Start Year 1992
Number of shared co-authors 0
Barry R Davies
Oncology R&D
Career Start Year 1992
Number of shared co-authors 0
Michael Schirner
Berlin Institute of Health (BIH) at Charite - Universitatsmedizin Berlin
Career Start Year 1991
Number of shared co-authors 0
Juha Kononen
Central Finland Hospital Nova
Career Start Year 1990
Number of shared co-authors 0
Emile E Voest
The Netherlands Cancer Institute
Career Start Year 1989
Number of shared co-authors 1
Christopher M Hovens
Royal Melbourne Hospital, The University of Melbourne
Career Start Year 1989
Number of shared co-authors 3
Fred C G J Sweep
Radboud University Medical Centre
Career Start Year 1987
Number of shared co-authors 2
Louis Gaboury
Institute for Research in Immunology and Cancer (IRIC), University of Montreal
Career Start Year 1986
Number of shared co-authors 0
Kenneth R Hess
The University of Texas MD Anderson Cancer Center
Career Start Year 1986
Number of shared co-authors 2
Silvano Bosari
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
Career Start Year 1986
Number of shared co-authors 0
James M Olson
Clinical Research Division, Fred Hutchinson Cancer Center
Career Start Year 1985
Number of shared co-authors 1
John A Copland
Mayo Clinic Jacksonville
Career Start Year 1982
Number of shared co-authors 0
David M Berman
Queen's University
Career Start Year 1982
Number of shared co-authors 2
Adrian L Harris
University of Oxford
Career Start Year 1981
Number of shared co-authors 4
Fabien Calvo
Universite de Paris-Cite
Career Start Year 1979
Number of shared co-authors 0
Jonathan A Pachter
Laufer Center for Physical and Quantitative Biology, Stony Brook University
Career Start Year 1979
Number of shared co-authors 0
Maria J Merino
National Cancer Institute, National Institutes of Health
Career Start Year 1977
Number of shared co-authors 0
Christopher C Benz
Buck Institute for Research on Aging
Career Start Year 1977
Number of shared co-authors 0
William E Grizzle
University of Alabama at Birmingham
Career Start Year 1974
Number of shared co-authors 1
Anna DeFazio
Westmead Hospital
Career Start Year 1972
Number of shared co-authors 2
John N Weinstein
The University of Texas MD Anderson Cancer Center
Career Start Year 1968
Number of shared co-authors 1
Peter J Dempsey
University of Colorado
Career Start Year 1968
Number of shared co-authors 2

Collaborators

Lloyd J Old
Ludwig Institute for Cancer Research
Co-authored papers 8
Thomas John
Peter MacCallum Cancer Centre
Co-authored papers 8
Paul Mitchell
Olivia Newton-John Cancer Research Institute
Co-authored papers 7
Terrance G Johns
Telethon Kids Institute
Co-authored papers 7
John M Mariadason
Olivia Newton-John Cancer Research Institute
Co-authored papers 7
Simon Knight
Churchill Hospital
Co-authored papers 6
Anthony T Papenfuss
Co-authored papers 6
Marzena Walkiewicz
Olivia Newton-John Cancer Research Institute
Co-authored papers 6
Bibhusal Thapa
Northern Hospital
Co-authored papers 5
Khashayar Asadi
Austin Hospital
Co-authored papers 5
Martin W Brechbiel
National Institutes of Health
Co-authored papers 4
Malaka Ameratunga
Australia Central Clinical School, Monash University
Co-authored papers 3
Richard J Simpson
Co-authored papers 3
Jonathan Cebon
Australia Olivia Newton-John Cancer Research Institute, La Trobe University
Co-authored papers 3
Paul C Boutros
University of California los angeles
Co-authored papers 3
Siddhartha Deb
Olivia Newton-John Cancer Research Institute
Co-authored papers 3
David N Watkins
Research Institute in Oncology and Hematology
Co-authored papers 3
Puey Ling Chia
Lee Kong Chian School of Medicine, Nanyang Technological University
Co-authored papers 2
Xihui Lin
Kresge Eye Institute/Wayne State University Department of Ophthalmology
Co-authored papers 2
Benjamin Solomon
Peter MacCallum Cancer Centre
Co-authored papers 2
Stephen Barnett
Royal Melbourne Hospital
Co-authored papers 2
Webster K Cavenee
Ludwig Institute for Cancer Research, University of California San Diego
Co-authored papers 2
Gareth Rivalland
Auckland City Hospital
Co-authored papers 2
Edouard C Nice
Monash University
Co-authored papers 2
Damien Bolton
University of Melbourne
Co-authored papers 2
Anderly C Chueh
Biomedicine Discovery Institute, Monash University
Co-authored papers 2
Prudence A Russell
St Vincent's Hospital
Co-authored papers 2
Judith A Clements
Co-authored papers 1
H-J Su Huang
Regeneron Pharmaceuticals Inc.
Co-authored papers 1
Kai St??hler
Universitatsklinikum
Co-authored papers 1
Release 1.2